1. Pharmacotherapy for Marijuana Dependence: A Double-blind, Placebo-controlled Pilot Study of Divalproex Sodium
- Author
-
Suzanne K. Vosburg, Edward Nunes, Frances Rudnick Levin, Stephen Donovan, David McDowell, Suzette M. Evans, and Evaristo Akerele
- Subjects
Adult ,Male ,Marijuana Abuse ,medicine.medical_specialty ,GABA Agents ,Health Behavior ,Administration, Oral ,Medicine (miscellaneous) ,Irritability ,Placebo ,law.invention ,Placebos ,Treatment and control groups ,Pharmacotherapy ,Double-Blind Method ,Randomized controlled trial ,law ,Internal medicine ,mental disorders ,Humans ,Medicine ,Psychiatry ,Cross-Over Studies ,business.industry ,Valproic Acid ,Crossover study ,Irritable Mood ,Clinical trial ,Psychiatry and Mental health ,Clinical Psychology ,Treatment Outcome ,Patient Compliance ,Female ,medicine.symptom ,business ,Psychosocial - Abstract
There is a noticeable lack of targeted treatment options for marijuana dependence, in particular pharmacologic approaches. This is the first study evaluating a targeted pharmacologic approach for marijuana dependence. The goals of the study were to determine if such patients would seek pharmacologic treatment, whether these patients could be retained in treatment using a design previously developed for cocaine-dependent patients, and especially whether divalproex sodium showed promise as a treatment agent for marijuana dependence. We found that marijuana-dependent patients will seek treatment, and such patients can be adequately maintained in a pharmacologic trial. Regardless of treatment group, patients reported a significant reduction in their frequency and amount of marijuana use as well as a reduction in irritability. Given the lack of proven effective treatments for marijuana dependence, pharmacotherapies should be sought. The design of a preliminary clinical trial should include a psychosocial/behavioral intervention emphasizing motivation and medication compliance and a placebo control group.
- Published
- 2004
- Full Text
- View/download PDF